Alzheimer's Prevention et al., 2023-07-31: Randomised trial of a multi-component precision-medicine protocol versus standard care in 73 people with mild cognitive impairment or early dementia, completed October 2025; methylene blue is one of several possible components, so no methylene-blue-specific effect can be extracted.
The goal of this clinical trial is to compare a precision medicine approach to the standard-of-care for people with mild cognitive impairment or early-stage dementia.
registry record
Alzheimer's Prevention et al., 2023-07-31: Randomised trial of a multi-component precision-medicine protocol versus standard care in 73 people with mild cognitive impairment or early dementia, completed October 2025; methylene blue is one of several possible components, so no methylene-blue-specific effect can be extracted. Record field transcription from the registry entry (labelled a record field, confidence MEDIUM). Interventional, randomised, phase 3 (self-designated). N=73 actual. Country: USA. Methylene blue, if used at all, is one item inside a personalised multi-drug and supplement protocol, not a standalone intervention; dose not specified in the registry summary. Comparator: standard of care. Sponsor: Alzheimer's Prevention and Reversal Project, Inc.; collaborator Four Winds Foundation. No results posted as of the registry record reviewed. Registry status: COMPLETED. No direct PDF exists for a registry record; source_url is the canonical study page.
